Delivery Order SPE2DB24D2205-SPE2DB26FDSTH
- Not listed
- The Defense Logistics Agency awarded a $34,728.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of October 27, 2025. This competitive award, issued on October 24, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a $41,877.63 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens under a firm fixed price contract type. The award was made on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this transaction. This delivery order constitutes a...
- The Defense Logistics Agency awarded a delivery order valued at $91,225.90 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This firm fixed-price delivery order, issued on September 18, 2025, with an ultimate completion date of September 19, 2025, represents a non-competitive award under an existing contract vehicle. The work will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters and a...
- The Defense Logistics Agency awarded a $10,594.36 firm fixed price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 2, 2025. This non-set-aside award was issued on August 29, 2025, to support federal medical supply needs. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a $34,197.25 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular focus on supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $2,648.59 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. The place of...
- The Defense Logistics Agency awarded a $9,272.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $15,153.17 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. The contract, issued on June 2, 2025, with completion targeted for June 3, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. This delivery order is a child contract executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a $69,322.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 9, 2025. This competitive award, issued on September 8, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's facility in...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB26FDSTHDelivery Order
The Defense Logistics Agency awarded a $27,608.80 delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's location in Conshohocken, Pennsylvania, with an ultimate completion date of October 27, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Department of Defense and veteran healthcare systems. As a prime vendor under DLA's pharmaceutical support framework, the company supplies a comprehensive range of brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices to support military healthcare programs worldwide. This award for Repatha, a PCSK9 inhibitor used in cardiovascular disease management, exemplifies the company's role in delivering specialized pharmaceutical products to meet the medical supply needs of federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.6k | 10/24/25 |